Within injectable finished-product lines for bovine, equine, porcine and companion animal respiratory and circulatory supportive therapy, sodium camphorsulfonate veterinary grade API is formulated as an aqueous solution at a nominal active concentration of 100 mg/mL, corresponding to 10.0% w/v. The manufacturing sequence begins with pre-dissolution of the API in Water for Injection at 20–25 °C under a nitrogen overlay to reduce oxidative degradation. In a 1,000 L stainless-steel vessel equipped with a magnetically coupled agitator, the bulk solution is stirred at 40–60 rpm; dissolution is typically complete within 30–45 min. The solution is passed through a 0.45 µm pre-filter and a 0.22 µm sterilizing-grade polyvinylidene fluoride cartridge, with differential pressure held below 0.8 bar to prevent filter blinding. After filtration, the bulk solution is filled into Type I borosilicate glass ampoules or vials under EU GMP Annex 1 restricted-access-barrier conditions. Terminal sterilization is validated at 121 °C for 15 min with an F0 value of at least 12 min, provided heat penetration studies demonstrate cold-spot lethality. Compliance criteria include sterility testing according to USP <71>, bacterial endotoxin limits according to USP <85>, particulate matter according to USP <788>, and fill volume uniformity according to the authorized specification. The formulation addition ratio is aligned with the labeled claim and assay-as-is purity: a 1,000 L batch with a target of 100.0 kg active substance at 98.0% API purity requires a charge of 102.04 kg. The terminal product type is a single-dose parenteral solution packaged in 10 mL, 20 mL and 50 mL amber glass containers.

What Limits Blend Uniformity in Water-Soluble Oral Powders for Swine and Poultry?

Water-soluble oral powders incorporating the API are produced for mass medication through drinking water lines in swine and poultry populations. The principal processing boundary is blend uniformity at API loadings above 40 wt%, when the low-bulk-density sulfonate particles adhere electrostatically to stainless steel contact surfaces. A representative 100 kg batch formula contains 40.0 kg active, 57.5 kg spray-dried lactose monohydrate, 2.0 kg anhydrous citric acid and 0.5 kg colloidal silicon dioxide; the addition ratio is therefore 40.0% w/w. Mixing is conducted in a 600 L ribbon blender at 12 rpm for 25 min under 40–50% relative humidity. Stratified in-process sampling follows the FDA Guidance for Industry: Powder Blends and Finished Dosage Units, with acceptance criteria of relative standard deviation not exceeding 5.0% and all individual results within 85.0–115.0% of target. The blended powder is filled into heat-sealed polyester/aluminum/polyethylene sachets of 100 g and 1,000 g. For administration, the 1,000 g unit is dissolved in 2,000–4,000 L drinking water to yield 0.25–0.50 g/L active concentration; exact dilution depends on species-specific daily water consumption and authorized dose. The terminal product type is a water-soluble powder or dry granulate for oral solution. Granulates are produced by drying a wet mass in a fluidised-bed granulator with inlet air temperature 50–55 °C and product temperature below 40 °C. Finished-product microbiological quality is assessed using USP <61> and USP <62>, with total aerobic microbial count below 10³ CFU/g and absence of Escherichia coli per 1 g. Residual solvent compliance is aligned with VICH GL18; veterinary medicinal product requirements follow Regulation (EU) 2019/6.

Where Premix Homogeneity Falls Below 50 g/kg in High-Fiber Carriers

Feed premix applications for calf and piglet supportive therapy require the API to be carried on a high-fiber or mineral matrix before final feed dilution. The addition ratio in an intermediary premix is typically 20–100 g/kg, with 50 g/kg (5.0% w/w) treated as the practical lower boundary for direct weighing accuracy. Below this concentration, a drum mixer at 25 rpm may fail to distribute low-density sodium camphorsulfonate uniformly through wheat middlings or rice hulls; the coefficient of variation exceeds 10% in 30% of sampled batches, a level that violates medicated premix homogeneity expectations. A more robust two-stage dilution is therefore used: a 100 g/kg pre-blend is produced in a 300 L planetary mixer with 80 kg ground limestone, 10 kg active and 10 kg light mineral oil as dust binder; this pre-blend is then diluted 1:20 with carrier in a horizontal ribbon mixer to yield 5 g/kg active. Sampling follows ISO 6497:2002, with at least 20 increments taken from the mixer and 10 final feed samples; analysis uses an HPLC-UV method validated under ICH Q7. Regulatory compliance rests on Regulation (EU) 2019/6 for veterinary medicinal products in feed, Directive 2002/32/EC for undesirable substances, and FAMI-QS for feed operator quality. The terminal product type is a dry nonsterile premix, packed in 25 kg multi-wall paper bags with polyethylene liner; cleaning validation carryover into non-medicated feed is controlled below 5 mg/kg. Dust extraction through a HEPA H13 filter is required because fine particulate sulfonate can irritate operator mucous membranes.

Compressed tablets and hard gelatin capsules for companion animals are manufactured at unit strengths derived from the authorized dose, with a 50 mg tablet and 200 mg core mass used here as a formulation example. The API addition ratio is therefore 25.0% w/w; the remaining core consists of microcrystalline cellulose, pregelatinized starch, crospovidone and magnesium stearate. Direct compression is avoided because the milled salt has poor compactibility and high ejection force. A high-shear wet granulation step is used, with a hypromellose 2910 binder solution at 3.0% w/w added to dry powders; the granulation end point is controlled by impeller power consumption and load cell response. The wet granules are dried in a fluidised-bed dryer at inlet air temperature 55 °C until loss on drying reaches 1.5–2.5% w/w. After dry milling through a 0.8 mm screen, granules are lubricated with magnesium stearate at 0.5% w/w and compressed on a 27-station rotary tablet press at main compression force 8–12 kN and precompression force 2–3 kN. In-process controls include tablet mass, hardness, friability and disintegration; finished product must satisfy uniformity of dosage units per USP <905>, disintegration per USP <701>, and dissolution per USP <711>, with a Q value of 80% at 30 min in 900 mL purified water at 37 °C using paddle apparatus at 50 rpm. Capsule filling operates on a tamping-type dosator at 60% relative humidity, using hard gelatin or hypromellose shells. The terminal product type is an immediate-release tablet or capsule for oral use in dogs and cats, packaged in PVC/aluminum blisters or HDPE bottles with desiccant. Stability protocols for Zone IVb include 40 °C/75% RH storage for 6 months; published data for this specific configuration is limited, so real-time protocols include assay, related substances, moisture content and dissolution.

Oral Drench Solutions for Neonatal Ruminants and pH-Dependent Stability

Oral liquid concentrates for neonatal calves, lambs and kids are manufactured as high-concentration solutions to reduce dosing volume during periods of respiratory insufficiency. A representative formulation contains 10.0 g/100 mL sodium camphorsulfonate in purified water, corresponding to 10.0% w/v; the addition ratio is 100 g/L before density correction. The manufacturing sequence charges 80% of the total water at 30–35 °C, adds the API under low-shear mixing, and adjusts pH to 5.5–6.5 with 0.1 N sodium hydroxide or 0.1 N hydrochloric acid as required. Sodium benzoate at 0.2% w/v and potassium sorbate at 0.1% w/v are added after cooling to 25 °C; the solution is filtered through a 5 µm coarse filter and filled into amber high-density polyethylene bottles or aluminum-foil-sealed dosing containers. Nonsterile oral liquid limits follow USP <61> and USP <62>, with total aerobic microbial count below 10² CFU/mL and absence of bile-tolerant gram-negative bacteria in 1 mL. Stability protocols follow VICH GL11, with pH, preservative assay and related substances monitored at 25 °C/60% RH and 40 °C/75% RH. Production-scale observations show pH drift when source water alkalinity exceeds 100 mg/L CaCO3; deionized water with conductivity below 1.3 µS/cm at 25 °C is specified. The terminal product type is an oral drench solution supplied in 250 mL, 500 mL and 1 L containers fitted with a calibrated dosing cap or oral syringe adapter. The solution should not be mixed with strong oxidizing agents or strongly acidic vehicles that could protonate the sulfonate group and reduce water solubility.